MA31008B1 - Polymorphes d'un antagoniste du recepteur mglur5 - Google Patents
Polymorphes d'un antagoniste du recepteur mglur5Info
- Publication number
- MA31008B1 MA31008B1 MA32012A MA32012A MA31008B1 MA 31008 B1 MA31008 B1 MA 31008B1 MA 32012 A MA32012 A MA 32012A MA 32012 A MA32012 A MA 32012A MA 31008 B1 MA31008 B1 MA 31008B1
- Authority
- MA
- Morocco
- Prior art keywords
- mglur5 receptor
- polymorphs
- receptor antagonist
- receptor
- acute
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
LA PRÉSENTE INVENTION CONCERNE DES SELS DE MONO-SULFATE ET D'HÉMI-SULFATE DE 2-CHLORO-4-[1-(4-FLUORO-PHÉNYL)-2,5-DIMÉTHYL-1H-IMIDAZOL-4-YLÉTHYNYL]-PYRIDINE, DES FORMES CRISTALLINES ET AMORPHES DE CEUX-CI AINSI QUE LEUR UTILISATION DANS DES PRÉPARATIONS PHARMACEUTIQUES. LES PRÉSENTS COMPOSÉS SONT ACTIFS SUR LE RÉCEPTEUR MGLUR5 POUR TRAITER DES MALADIES ASSOCIÉES À CE RÉCEPTEUR, TELLES QUE LES TROUBLES NEUROLOGIQUES AIGUS ET/OU CHRONIQUES, ET NOTAMMENT L'ANXIÉTÉ, OU POUR TRAITER LA DOULEUR CHRONIQUE ET AIGUË OU OFFRIR UNE PROTECTION CONTRE LES ATTEINTES HÉPATIQUES, L'INSUFFISANCE INDUITE PAR UN MÉDICAMENT OU UNE MALADIE, L'INCONTINENCE URINAIRE, L'OBÉSITÉ, LE SYNDROME DE L'X FRAGILE OU L'AUTISME.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87639806P | 2006-12-21 | 2006-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31008B1 true MA31008B1 (fr) | 2009-12-01 |
Family
ID=39186951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32012A MA31008B1 (fr) | 2006-12-21 | 2009-06-17 | Polymorphes d'un antagoniste du recepteur mglur5 |
Country Status (33)
Country | Link |
---|---|
US (2) | US8063076B2 (fr) |
EP (1) | EP2125779B1 (fr) |
JP (1) | JP5405311B2 (fr) |
KR (1) | KR101148580B1 (fr) |
CN (1) | CN101568531B (fr) |
AR (1) | AR064654A1 (fr) |
AU (1) | AU2007336369B2 (fr) |
BR (1) | BRPI0720954A2 (fr) |
CA (1) | CA2673444C (fr) |
CL (1) | CL2007003695A1 (fr) |
CO (1) | CO6210731A2 (fr) |
CY (1) | CY1117810T1 (fr) |
DK (1) | DK2125779T3 (fr) |
EC (1) | ECSP099431A (fr) |
ES (1) | ES2577391T3 (fr) |
HR (1) | HRP20160950T1 (fr) |
HU (1) | HUE029324T2 (fr) |
IL (1) | IL199181A (fr) |
MA (1) | MA31008B1 (fr) |
MX (1) | MX2009006694A (fr) |
MY (1) | MY148217A (fr) |
NO (1) | NO342451B1 (fr) |
NZ (1) | NZ577440A (fr) |
PE (1) | PE20081484A1 (fr) |
PL (1) | PL2125779T3 (fr) |
PT (1) | PT2125779T (fr) |
RS (1) | RS54853B1 (fr) |
RU (1) | RU2460728C2 (fr) |
SI (1) | SI2125779T1 (fr) |
TW (1) | TWI347320B (fr) |
UA (1) | UA96970C2 (fr) |
WO (1) | WO2008074697A1 (fr) |
ZA (1) | ZA200904289B (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007336369B2 (en) | 2006-12-21 | 2013-01-17 | F. Hoffmann-La Roche Ag | Polymorphs of a mGluR5 receptor antagonist |
US20120039999A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
KR20140018286A (ko) | 2011-03-18 | 2014-02-12 | 노파르티스 아게 | 파킨슨병에서의 도파민 유발 이상운동증에서 사용하기 위한 알파 7 니코틴성 아세틸콜린 수용체 활성화제 및 mGluR5 길항제의 조합물 |
EP2837631A1 (fr) * | 2013-08-14 | 2015-02-18 | Merck & Cie | Nouveau sel stable d'acide 5,10-méthylène-(6R)-tétrahydrofolique |
GB201317022D0 (en) * | 2013-09-25 | 2013-11-06 | Addex Pharmaceuticals Sa | Polymorphs |
CA2936377A1 (fr) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Composes et compositions pour le traitement de tumeurs exprimant egfr |
CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-egfr组合 |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
WO2021245281A1 (fr) | 2020-06-05 | 2021-12-09 | Noema Pharma Ag | Procédés de traitement de la sclérose tubéreuse de bourneville |
WO2022023519A1 (fr) * | 2020-07-30 | 2022-02-03 | Noema Pharma Ag | Méthodes de traitement de névralgie du trijumeau |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3303199A (en) * | 1963-07-15 | 1967-02-07 | Geigy Chem Corp | Certain imidazolone derivatives and process for making same |
US3341548A (en) * | 1964-04-29 | 1967-09-12 | Hoffmann La Roche | Nitroimidazoles and their preparation |
DE2035905A1 (de) | 1970-07-20 | 1972-02-03 | Chemische Fabrik Stockhausen & Cie.,4150Krefeld | Imidazolverbindungen und deren Herstellungsverfahren |
CA1174673A (fr) * | 1981-02-27 | 1984-09-18 | Walter Hunkeler | Imidazodiazepines |
US4508560A (en) * | 1981-11-11 | 1985-04-02 | Ciba Geigy Corporation | Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use |
US4711962A (en) * | 1984-10-18 | 1987-12-08 | Stauffer Chemical Company | Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles |
HU217958B (hu) | 1989-06-30 | 2000-05-28 | E. I. Du Pont De Nemours And Co. | Helyettesített imidazolszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
CA2297732C (fr) | 1997-08-14 | 2008-04-29 | F. Hoffmann-La Roche Ag | Ethers heterocycliques de vinyle utiles contre des troubles neurologiques |
CA2383524C (fr) | 1999-08-31 | 2010-09-28 | Merck & Co., Inc. | Composes heterocycliques et procedes d'utilisation de ceux-ci |
US7205297B2 (en) | 2000-07-24 | 2007-04-17 | Krenitsky Pharmaceuticals, Inc. | Substituted 5-alkynyl pyrimidines having neurotrophic activity |
CN1257894C (zh) | 2000-12-04 | 2006-05-31 | 弗·哈夫曼-拉罗切有限公司 | 作为谷氨酸受体拮抗剂的苯基乙烯基或苯基乙炔基衍生物 |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
CA2470612A1 (fr) * | 2001-12-19 | 2003-07-03 | Merck & Co., Inc. | Imidazoles substitues par heteroaryle modulateurs du recepteur metabotropique du glutamate de type 5 |
TWI292318B (en) * | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
US7091222B2 (en) | 2003-07-03 | 2006-08-15 | Hoffmann-La Roche Inc. | Imidazole derivatives |
US7452909B2 (en) | 2003-09-04 | 2008-11-18 | Hoffman-La Roche Inc. | Imidazole derivatives |
EP1756086B1 (fr) * | 2004-06-01 | 2008-06-04 | F.Hoffmann-La Roche Ag | Pyridin-4-yl-ethynyl-imidazoles et pyrazoles, antagonistes du recepteur mglur5 |
AU2007336369B2 (en) | 2006-12-21 | 2013-01-17 | F. Hoffmann-La Roche Ag | Polymorphs of a mGluR5 receptor antagonist |
-
2007
- 2007-12-11 AU AU2007336369A patent/AU2007336369B2/en active Active
- 2007-12-11 ES ES07857408.4T patent/ES2577391T3/es active Active
- 2007-12-11 HU HUE07857408A patent/HUE029324T2/en unknown
- 2007-12-11 CA CA2673444A patent/CA2673444C/fr active Active
- 2007-12-11 MX MX2009006694A patent/MX2009006694A/es active IP Right Grant
- 2007-12-11 SI SI200731792A patent/SI2125779T1/sl unknown
- 2007-12-11 WO PCT/EP2007/063721 patent/WO2008074697A1/fr active Application Filing
- 2007-12-11 RU RU2009123135/04A patent/RU2460728C2/ru active
- 2007-12-11 DK DK07857408.4T patent/DK2125779T3/en active
- 2007-12-11 MY MYPI20092393A patent/MY148217A/en unknown
- 2007-12-11 RS RS20160461A patent/RS54853B1/sr unknown
- 2007-12-11 EP EP07857408.4A patent/EP2125779B1/fr active Active
- 2007-12-11 PT PT78574084T patent/PT2125779T/pt unknown
- 2007-12-11 UA UAA200907474A patent/UA96970C2/ru unknown
- 2007-12-11 JP JP2009541986A patent/JP5405311B2/ja active Active
- 2007-12-11 BR BRPI0720954-1A patent/BRPI0720954A2/pt not_active Application Discontinuation
- 2007-12-11 KR KR1020097012810A patent/KR101148580B1/ko active IP Right Grant
- 2007-12-11 NZ NZ577440A patent/NZ577440A/en unknown
- 2007-12-11 CN CN2007800475969A patent/CN101568531B/zh active Active
- 2007-12-11 PL PL07857408.4T patent/PL2125779T3/pl unknown
- 2007-12-14 PE PE2007001802A patent/PE20081484A1/es not_active Application Discontinuation
- 2007-12-17 US US11/957,515 patent/US8063076B2/en active Active
- 2007-12-19 CL CL200703695A patent/CL2007003695A1/es unknown
- 2007-12-19 TW TW096148786A patent/TWI347320B/zh active
- 2007-12-21 AR ARP070105822A patent/AR064654A1/es not_active Application Discontinuation
-
2009
- 2009-06-04 IL IL199181A patent/IL199181A/en active IP Right Grant
- 2009-06-05 CO CO09058653A patent/CO6210731A2/es not_active Application Discontinuation
- 2009-06-15 EC EC2009009431A patent/ECSP099431A/es unknown
- 2009-06-17 MA MA32012A patent/MA31008B1/fr unknown
- 2009-06-18 ZA ZA200904289A patent/ZA200904289B/xx unknown
- 2009-06-19 NO NO20092357A patent/NO342451B1/no unknown
-
2011
- 2011-10-14 US US13/273,266 patent/US8329912B2/en active Active
-
2016
- 2016-07-19 CY CY20161100705T patent/CY1117810T1/el unknown
- 2016-07-26 HR HRP20160950TT patent/HRP20160950T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31008B1 (fr) | Polymorphes d'un antagoniste du recepteur mglur5 | |
MX2007005570A (es) | Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos. | |
MA33053B1 (fr) | Inhibiteurs de la poly(adp-ribose) polymerase (parp) | |
MA28481B1 (fr) | Dérivés d'imidazole pour le traitement de troubles neurodégénératifs | |
MA32804B1 (fr) | Antagonistes d'isonicotinamide des récepteurs de l'orexine | |
TNSN08027A1 (en) | Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use of same | |
EP2331095A4 (fr) | Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci | |
MA31260B1 (fr) | 3-imidazolyl-indoles pour le traitement de maladies proliferatives | |
MA33593B1 (fr) | Composés hétérocycliques et leurs utilisations | |
MA31707B1 (fr) | Dérivés de benzimidazole et d'indole substitués par de l'oxadiazole et oxazole comme inhibiteurs de dgat1 | |
WO2007087151A3 (fr) | Méthode de traitement d'un dysfonctionnement cognitif | |
WO2008007211A8 (fr) | Composés de carboxyamide bicycliques à n-bicycloalkyle substitué | |
NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
US20100273778A1 (en) | Treatment of osteoarthritis pain | |
MA30631B1 (fr) | Inhibiteurs de tyrosine kinase | |
NZ597648A (en) | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats | |
EA201000617A1 (ru) | Комбинация, включающая производные пурина и другие соединения, и ее применение для лечения воспалительных и обструктивных заболеваний дыхательных путей | |
BRPI0921692A2 (pt) | composto carbamato ou o sal do mesmo | |
MA33753B1 (fr) | Nouveaux camphènes arylés, procédés de préparation et utilisations de ceux-ci | |
MY142085A (en) | Imidazole derivatives | |
TN2009000257A1 (fr) | Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1, m2 et m3. | |
MA31930B1 (fr) | Utilisation de la méquitazine sous la forme de racémate ou d'énantiomères pour la préparation d'un médicament destiné au traitement ou à la prévention de pathologies impliquant les récepteurs histaminiques h4 | |
EA201000440A1 (ru) | Способ лечения центральной нервной системы и беспорядочных болей | |
AU2001265185A1 (en) | Use of ace inhibitors for treatment of patients suffering from behavioral disorders | |
FR2872045B1 (fr) | Medicaments pour le traitement specifique de symptomes de la maladie de parkinson |